Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis
Authors:
- Seung-Jun HwangSHSeung-Jun Hwang
- Bongkun ChoiBCBongkun Choi
- Soon-Suk KangSKSoon-Suk Kang
- Jae-Ho ChangJCJae-Ho Chang
- Yong-Gil KimYong-Gil Kim
- Yeon-Ho ChungYCYeon-Ho Chung
- Dong Hyun SohnDSDong Hyun Sohn
- Min Wook SoMSMin Wook So
- Chang-Keun LeeCLChang-Keun Lee
- William H RobinsonWRWilliam H Robinson
- Eun-Ju ChangECEun-Ju Chang
Open Access
- 20 January 2012
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (1) , R14
Abstract
Introduction: Interleukin-34 (IL-34) is a recently defined cytokine, showing a functional overlap with macrophage colony stimulating factor (M-CSF). This study was undertaken to address the expression of IL-34 in rheumatoid arthritis (RA) patients and to investigate its regulation and pathogenic role in RA. Methods: IL-34 levels were determined in the RA synovium, synovial fluid (SF) and fibroblast-like synovial cells (FLS) by immunohistochemistry, real-time PCR, enzyme-linked immunosorbent assay and immunoblotting. RA activity was assessed using Disease Activity Score 28 (DAS28) activity in the plasma collected at baseline and one year after treatment. Conditioned media (CM) were prepared from RA FLS culture with tumor necrosis factor alpha (TNFα) for 24 hours and used for functional assay. Results: IL-34 was expressed in the synovium, SF, and FLS from RA patients. The production of IL-34 in FLS was up-regulated by TNFα in RA samples compared with osteoarthritis (OA) patients. Importantly, the preferential induction of IL-34 rather than M-CSF by TNFα in RAFLS was mediated by the transcription factor nuclear factor kappa B (NF-κB) and activation of c-Jun N-terminal kinase (JNK). IL-34 elevation in plasma from RA patients was decreased after the administration of disease-modifying anti-rheumatic drugs (DMARDs) in accordance with a decrease in DAS28. CM from RAFLS cultured with TNFα promoted chemotactic migration of human peripheral blood mononuclear cells (PBMCs) and subsequent osteoclast (OC) formation, effects that were attenuated by an anti-IL-34 antibody. Conclusions: These data provide novel information about the production of IL-34 in RA FLS and indicate that IL-34 is an additional osteoclastogenic factor regulated by TNFα in RA, suggesting a discrete role of IL-34 in inflammatory RA diseases.Keywords
This publication has 47 references indexed in Scilit:
- The Critical Role of IL-34 in OsteoclastogenesisPLOS ONE, 2011
- Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cellsJournal of Leukocyte Biology, 2010
- c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritisArthritis Research & Therapy, 2010
- Effect of interleukin‐32γ on differentiation of osteoclasts from CD14+ monocytesArthritis & Rheumatism, 2010
- TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral bloodArthritis Research & Therapy, 2008
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- Vascular endothelial growth factor receptors in osteoclast differentiation and functionBiochemical and Biophysical Research Communications, 2005
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988